Webinar: Novel Therapies in Bleeding Disorders-Novel Therapies in Bleeding Disorders

Video Transcription

Video Summary

The webinar introduced Heather Baumann, a pediatric bleeding disorders nurse, who reviewed past, current, and future treatments for inherited bleeding disorders. She explained normal clotting, the roles of platelets, von Willebrand factor, and clotting factors, and compared primary and secondary hemostasis.<br /><br />The talk covered von Willebrand disease as the most common inherited bleeding disorder, describing its three types, typical symptoms, and treatments such as DDAVP, tranexamic acid, and von Willebrand factor concentrates. She then reviewed hemophilia A and B, inheritance patterns linked to the X chromosome, and severity based on factor levels. Historical treatment evolution was traced from whole blood and plasma products to safer heat-treated and recombinant factors, then to standard half-life and extended half-life factor replacement.<br /><br />A major focus was emicizumab, a subcutaneous factor VIII mimetic used in hemophilia A, especially in patients with inhibitors, though it does not treat active bleeds and is not for hemophilia B. She also discussed ultra-extended half-life products, gene therapy for hemophilia B, and rebalancing agents in development. The presentation ended with exciting future possibilities, including novel delivery methods and emerging experimental therapies.

Keywords

inherited bleeding disorders

von Willebrand disease

hemophilia A

hemophilia B

hemostasis

emicizumab

factor replacement therapy

gene therapy

bleeding disorder treatments